A Phase 3 Study of ONO-4538/BMS-936558

Authors
Category Primary study
Registry of TrialsJapan Pharmaceutical Information Center
Year 2012
INTERVENTION: Intervention name : ONO‐4538/BMS‐936558 Dosage And administration of the intervention : Intravenous administration Control intervention name : Afinitor INN of the control intervention : Everolimus Dosage And administration of the control intervention : Per os (by mouth) CONDITION: Advanced or Metastatic Clear‐Cell Renal Cell Carcinoma PRIMARY OUTCOME: Overall survival SECONDARY OUTCOME: Progression‐free survival, Objective response rate, Safety, etc. INCLUSION CRITERIA: 1. Histologic confirmation of Renal cell carcinoma (RCC) with clear‐cell component 2. Advanced/metastatic RCC 3. Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Epistemonikos ID: cde449bb45561d3803796dba0eaf8af91c3319e6
First added on: Aug 22, 2024